PRT3789
- Generic Name
- PRT3789
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 2
Recruiting
- Conditions
- Advanced Solid TumorEsophageal CancerMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06682806
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research, Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 226
- Registration Number
- NCT05639751
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath